An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA

M. C. Yen, T. Y. Weng, Y. L. Chen, C. C. Lin, C. Y. Chen, C. Y. Wang, H. L. Chao, C. S. Chen, M. D. Lai

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Histone deacetylase (HDAC) inhibitors are used in treating certain human malignancies. Our laboratories demonstrated their capability in enhancing antitumor effect of DNA vaccine driven by an RNA polymerase II (RNA pol II) promoter. However, it is unknown whether HDAC inhibitors enhance the therapeutic short hairpin RNA (shRNA) expressed by an RNA polymerase III (RNA pol III) promoter. We investigated whether HDAC inhibitors augmented antitumor effect of indoleamine 2,3 dioxygenase (IDO) shRNA. HDAC inhibitor OSU-HDAC42 and suberoylanilide hydroxamic acid enhanced RNA pol III-driven U6 and H1 promoter activity in three different cell types in vitro: 293, NIH3T3 and dendritic cell line DC2.4. Subcutaneous injection of OSU-HDAC42 enhanced U6 and H1 promoter activity on abdominal skin of mice in vivo. Combination of IDO shRNA and OSU-HDAC42 increased antitumor effect of IDO shRNA in MBT-2 murine bladder tumor model. IDO shRNA induced tumor-infiltrating CD8+ and CD4+ T cells, whereas OSU-HDAC42 treatment induced tumor-infiltrating CD4 + T cells. Combination of OSU-HDAC42 and IDO shRNA further induced tumor-infiltrating natural killer cells and enhanced interferon-γ in lymphocytes, but suppressed interleukin (IL)-4 expression of lymphocytes. In addition, OSU-HDAC42 treatment did not alter mRNA expression of IL-12 and tumor necrosis factor-α. In conclusion, HDAC inhibitor OSU-HDAC42 may serve as adjuvant of the therapeutic shRNA expressed by an RNA pol III promoter.

Original languageEnglish
Pages (from-to)351-357
Number of pages7
JournalCancer Gene Therapy
Volume20
Issue number6
DOIs
Publication statusPublished - Jun 1 2013
Externally publishedYes

Fingerprint

Drug Synergism
Phenylbutyrates
Indoleamine-Pyrrole 2,3,-Dioxygenase
RNA Polymerase III
NIH 3T3 Cells
DNA Vaccines
Histone Deacetylase Inhibitors
Histone Deacetylases
Genetic Promoter Regions
Dendritic Cells
Small Interfering RNA
Neoplasms
Therapeutics
Lymphocytes
T-Lymphocytes
RNA Polymerase II
Subcutaneous Injections
Interleukin-12
Urinary Bladder Neoplasms
Natural Killer Cells

Keywords

  • H1 promoter
  • IDO shRNA
  • indoleamine 2,3-dioxygenase
  • OSU-HDAC42
  • RNA polymerase I.I.I.
  • U6 promoter

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA. / Yen, M. C.; Weng, T. Y.; Chen, Y. L.; Lin, C. C.; Chen, C. Y.; Wang, C. Y.; Chao, H. L.; Chen, C. S.; Lai, M. D.

In: Cancer Gene Therapy, Vol. 20, No. 6, 01.06.2013, p. 351-357.

Research output: Contribution to journalArticle

Yen, MC, Weng, TY, Chen, YL, Lin, CC, Chen, CY, Wang, CY, Chao, HL, Chen, CS & Lai, MD 2013, 'An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA', Cancer Gene Therapy, vol. 20, no. 6, pp. 351-357. https://doi.org/10.1038/cgt.2013.27
Yen, M. C. ; Weng, T. Y. ; Chen, Y. L. ; Lin, C. C. ; Chen, C. Y. ; Wang, C. Y. ; Chao, H. L. ; Chen, C. S. ; Lai, M. D. / An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA. In: Cancer Gene Therapy. 2013 ; Vol. 20, No. 6. pp. 351-357.
@article{9e744cf983124309a9d554e1bbeb87ca,
title = "An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA",
abstract = "Histone deacetylase (HDAC) inhibitors are used in treating certain human malignancies. Our laboratories demonstrated their capability in enhancing antitumor effect of DNA vaccine driven by an RNA polymerase II (RNA pol II) promoter. However, it is unknown whether HDAC inhibitors enhance the therapeutic short hairpin RNA (shRNA) expressed by an RNA polymerase III (RNA pol III) promoter. We investigated whether HDAC inhibitors augmented antitumor effect of indoleamine 2,3 dioxygenase (IDO) shRNA. HDAC inhibitor OSU-HDAC42 and suberoylanilide hydroxamic acid enhanced RNA pol III-driven U6 and H1 promoter activity in three different cell types in vitro: 293, NIH3T3 and dendritic cell line DC2.4. Subcutaneous injection of OSU-HDAC42 enhanced U6 and H1 promoter activity on abdominal skin of mice in vivo. Combination of IDO shRNA and OSU-HDAC42 increased antitumor effect of IDO shRNA in MBT-2 murine bladder tumor model. IDO shRNA induced tumor-infiltrating CD8+ and CD4+ T cells, whereas OSU-HDAC42 treatment induced tumor-infiltrating CD4 + T cells. Combination of OSU-HDAC42 and IDO shRNA further induced tumor-infiltrating natural killer cells and enhanced interferon-γ in lymphocytes, but suppressed interleukin (IL)-4 expression of lymphocytes. In addition, OSU-HDAC42 treatment did not alter mRNA expression of IL-12 and tumor necrosis factor-α. In conclusion, HDAC inhibitor OSU-HDAC42 may serve as adjuvant of the therapeutic shRNA expressed by an RNA pol III promoter.",
keywords = "H1 promoter, IDO shRNA, indoleamine 2,3-dioxygenase, OSU-HDAC42, RNA polymerase I.I.I., U6 promoter",
author = "Yen, {M. C.} and Weng, {T. Y.} and Chen, {Y. L.} and Lin, {C. C.} and Chen, {C. Y.} and Wang, {C. Y.} and Chao, {H. L.} and Chen, {C. S.} and Lai, {M. D.}",
year = "2013",
month = "6",
day = "1",
doi = "10.1038/cgt.2013.27",
language = "English",
volume = "20",
pages = "351--357",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA

AU - Yen, M. C.

AU - Weng, T. Y.

AU - Chen, Y. L.

AU - Lin, C. C.

AU - Chen, C. Y.

AU - Wang, C. Y.

AU - Chao, H. L.

AU - Chen, C. S.

AU - Lai, M. D.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Histone deacetylase (HDAC) inhibitors are used in treating certain human malignancies. Our laboratories demonstrated their capability in enhancing antitumor effect of DNA vaccine driven by an RNA polymerase II (RNA pol II) promoter. However, it is unknown whether HDAC inhibitors enhance the therapeutic short hairpin RNA (shRNA) expressed by an RNA polymerase III (RNA pol III) promoter. We investigated whether HDAC inhibitors augmented antitumor effect of indoleamine 2,3 dioxygenase (IDO) shRNA. HDAC inhibitor OSU-HDAC42 and suberoylanilide hydroxamic acid enhanced RNA pol III-driven U6 and H1 promoter activity in three different cell types in vitro: 293, NIH3T3 and dendritic cell line DC2.4. Subcutaneous injection of OSU-HDAC42 enhanced U6 and H1 promoter activity on abdominal skin of mice in vivo. Combination of IDO shRNA and OSU-HDAC42 increased antitumor effect of IDO shRNA in MBT-2 murine bladder tumor model. IDO shRNA induced tumor-infiltrating CD8+ and CD4+ T cells, whereas OSU-HDAC42 treatment induced tumor-infiltrating CD4 + T cells. Combination of OSU-HDAC42 and IDO shRNA further induced tumor-infiltrating natural killer cells and enhanced interferon-γ in lymphocytes, but suppressed interleukin (IL)-4 expression of lymphocytes. In addition, OSU-HDAC42 treatment did not alter mRNA expression of IL-12 and tumor necrosis factor-α. In conclusion, HDAC inhibitor OSU-HDAC42 may serve as adjuvant of the therapeutic shRNA expressed by an RNA pol III promoter.

AB - Histone deacetylase (HDAC) inhibitors are used in treating certain human malignancies. Our laboratories demonstrated their capability in enhancing antitumor effect of DNA vaccine driven by an RNA polymerase II (RNA pol II) promoter. However, it is unknown whether HDAC inhibitors enhance the therapeutic short hairpin RNA (shRNA) expressed by an RNA polymerase III (RNA pol III) promoter. We investigated whether HDAC inhibitors augmented antitumor effect of indoleamine 2,3 dioxygenase (IDO) shRNA. HDAC inhibitor OSU-HDAC42 and suberoylanilide hydroxamic acid enhanced RNA pol III-driven U6 and H1 promoter activity in three different cell types in vitro: 293, NIH3T3 and dendritic cell line DC2.4. Subcutaneous injection of OSU-HDAC42 enhanced U6 and H1 promoter activity on abdominal skin of mice in vivo. Combination of IDO shRNA and OSU-HDAC42 increased antitumor effect of IDO shRNA in MBT-2 murine bladder tumor model. IDO shRNA induced tumor-infiltrating CD8+ and CD4+ T cells, whereas OSU-HDAC42 treatment induced tumor-infiltrating CD4 + T cells. Combination of OSU-HDAC42 and IDO shRNA further induced tumor-infiltrating natural killer cells and enhanced interferon-γ in lymphocytes, but suppressed interleukin (IL)-4 expression of lymphocytes. In addition, OSU-HDAC42 treatment did not alter mRNA expression of IL-12 and tumor necrosis factor-α. In conclusion, HDAC inhibitor OSU-HDAC42 may serve as adjuvant of the therapeutic shRNA expressed by an RNA pol III promoter.

KW - H1 promoter

KW - IDO shRNA

KW - indoleamine 2,3-dioxygenase

KW - OSU-HDAC42

KW - RNA polymerase I.I.I.

KW - U6 promoter

UR - http://www.scopus.com/inward/record.url?scp=84879410199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879410199&partnerID=8YFLogxK

U2 - 10.1038/cgt.2013.27

DO - 10.1038/cgt.2013.27

M3 - Article

C2 - 23681283

AN - SCOPUS:84879410199

VL - 20

SP - 351

EP - 357

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 6

ER -